tooluniverse-clinical-trial-design

Name: tooluniverse-clinical-trial-design
Availability: InStock
Author: avatar-arts

Analyze clinical trial feasibility with enrollment projections and regulatory pathway guidance.

Updated May 11, 2026

Search Tags:#feasibility #risk-management #biomarker #clinical-trial #endpoint-selection #enrollment-projections #regulatory-pathways

Ready to run

npx skills add https://github.com/AvaTar-ArTs/my-supremepowers --skill tooluniverse-clinical-trial-design

💬 Prompt for ChatGPT / Claude Chat▼

Please help me install this Agent Skill.
Skill: tooluniverse-clinical-trial-design
Source: https://github.com/AvaTar-ArTs/my-supremepowers/tree/main/qwen_skills/tooluniverse-clinical-trial-design
Command: npx skills add https://github.com/AvaTar-ArTs/my-supremepowers --skill tooluniverse-clinical-trial-design

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

Systematically assesses clinical trial feasibility by sizing patient populations, estimating biomarker prevalence, selecting endpoints, and mapping regulatory pathways to accelerate study design.

Core Features & Use Cases

Feasibility profiling for Phase 1/2 biomarker-driven trials
Enrollment projections, endpoint strategy guidance, and regulatory pathway assessment
Support for basket and umbrella trial designs with risk mitigation planning

Quick Start

Run a Phase 1/2 biomarker-driven feasibility assessment for your indication and generate enrollment projections, endpoint options, and regulatory pathway guidance.

Frequently Asked Questions about tooluniverse-clinical-trial-design

High-intent search queries and answers about installing and using this skill.

FAQPage Schema

How do I assess clinical trial feasibility for a biomarker-driven oncology study?▼

Clinical trial feasibility is assessed by sizing patient populations, estimating biomarker prevalence, selecting evidence-grade endpoints, and mapping regulatory pathways. This process generates a defensible feasibility score with risk mitigations for Phase 1/2 and basket trials.

Can I use this for enrollment projections and endpoint selection in basket and umbrella trials?▼

Yes, enrollment projections and endpoint strategy guidance are core features. It supports complex basket and umbrella trial designs across oncology indications, integrating population sizing and risk mitigation planning.

What data sources are used for regulatory pathway assessment and biomarker prevalence estimation?▼

Regulatory pathway assessment and biomarker prevalence estimation use documented sources including OpenTargets, ClinVar, gnomAD, FDA Orange Book, and clinical trial registries to ensure evidence-grade inputs and outputs.

Does this feasibility profiling tool support Phase 1/2 risk management and mitigation planning?▼

Yes, feasibility profiling explicitly includes risk mitigation planning. It produces a defensible feasibility score for Phase 1/2 biomarker-driven trials while documenting risk-management strategies and regulatory pathways.

What is the best way to size patient populations for a biomarker-driven clinical trial?▼

The best way to size patient populations is analyzing biomarker prevalence and indication-specific data using ToolUniverse. This yields defensible feasibility scores, enrollment projections, and evidence-grade endpoints.

Are there limitations when applying this clinical trial design approach to non-oncology indications?▼

This approach is specifically applied across oncology indications for Phase 1/2 and biomarker-driven studies. Feasibility profiling, endpoint selection, and enrollment projections are optimized for oncology basket and umbrella designs.